PureTech Health plc(PRTC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 5 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PRTC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for PureTech Health plc (PRTC), a Healthcare sector company. PRTC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 5 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2024), PureTech Health plc reports quarterly revenue of $4.8M, net income of $27.8M. Top institutional holders of PRTC by reported 13-F value include Pentwater Capital Management, MILLENNIUM MANAGEMENT, Persistent Asset Partners Ltd, based on the most recent SEC filings. PRTC trades on the Nasdaq exchange and files with the SEC under CIK 1782999. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PureTech Health plc directly from SEC EDGAR.
Revenue
FY 2024
$4.8M
Net Income
FY 2024
$27.8M
AI Insight: PRTC Financial Trends
PureTech Health financial data is entirely unavailable across all metrics for the five-year period through Q4 2024.
• No revenue, profitability, or cash flow data available for any quarter from Q4 2020 through Q4 2024.
⚠ Complete absence of financial reporting data raises questions about data availability or reporting practices.
AI Insight: PRTC Ratio Trends
Financial ratio data unavailable across all periods, preventing meaningful trend analysis for PureTech Health.
• No operating margin, profitability, or return metrics available from Q4 2020 through Q4 2024.
⚠ Complete absence of key financial ratios suggests potential data collection issues or non-standard reporting.
Get alerted when PRTC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PureTech Health plc including:
Top Institutional Holders of PRTC
Pentwater Capital Management LP
$1.0M70,000 shMILLENNIUM MANAGEMENT LLC
$882.8K59,525 shPersistent Asset Partners Ltd
$26.1K1,759 shDIADEMA PARTNERS LP
$11.3K7,924 shUBS Group AG
$297.0020 sh
| Fund | Value | Shares |
|---|---|---|
| Pentwater Capital Management LP | $1.0M | 70,000 |
| MILLENNIUM MANAGEMENT LLC | $882.8K | 59,525 |
| Persistent Asset Partners Ltd | $26.1K | 1,759 |
| DIADEMA PARTNERS LP | $11.3K | 7,924 |
| UBS Group AG | $297.00 | 20 |
More Healthcare Companies
View all Healthcare →Put PRTC on your watchlist
Track score changes the day PureTech Health plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PRTC a good stock to buy?
13F Pro's AI-powered analysis of PureTech Health plc (PRTC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRTC are available on the PRTC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PRTC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRTC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PureTech Health plc's investment landscape.